MedCap (Q3 review): Healthy Q3 figures - Redeye

Redeye updates its estimates and valuation following MedCap’s Q3 2025 report. Both sales and adjusted EBITA beat our forecasts. Encouragingly, organic growth of c9% y/y represented a continued sequential improvement. M&A activity has ramped year-to-date. We believe soft organic growth comparables and substantial financial M&A capacity bode well for coming quarters, though the share’s price seemingly reflects this potential.

Länk till analysen i sin helhet: https://www.redeye.se/research/1133498/medcap-q3-review-healthy-q3-figures?utm_source=finwire&utm_medium=RSS